Even with powerful injectable therapies, there remains a group of patients for whom bariatric surgery is still the stronger long-term answer
Diplomada de Medicina Esttica, Universidad Andrs Bello
At the same time, it has a similar function to GPX7, which can increase the PDI activity of ER redox protein 1 (ERO1), promote the oxidative folding of endoplasmic reticulum proteins, and reduce oxidative stress (Yoboue et al., 2017)

What the FDA Requires in the BLA Efficacy Data: TRIUMPH-4: 28.7% weight loss Complete TRIUMPH-1: 28.3% weight loss Complete TRIUMPH-2: 20.8% weight loss (obesity + diabetes) Complete TRIUMPH-3: 22.6% weight loss (obesity + cardiovascular disease) Complete, MACE data not statistically significant Safety Data: Side effect profile across all four populations Short-term and medium-term adverse events, including the dysesthesia signal (up to 20.9% at 12mg) Drug interactions, especially with diabetes medications Manufacturing Data: Scale-up capability for millions of doses per month Quality control and stability data Cold chain distribution logistics Realistic Approval Scenarios With the BLA filing point now expected (Q1 2027), the remaining uncertainty is largely in the FDA review itself not in whether or when Lilly files

Relevant biomarkers documented in the published literature include serum cytokine panels (IL-6, TNF-, IL-10 for inflammatory profiling), skin biopsy histology (collagen density, fibroblast count), joint fluid sampling for proteoglycan and inflammatory marker analysis, and functional assessments (gait scoring, activity level quantification)
In addition, it protects the organs against a cytokine overproduction, regulating the immune response and buffering oxidative damage